Prof. Sherko Kuemmel and the WSG Study Group presented key findings from the ADAPT HR+/HER2- chemotherapy trial, refining treatment strategies for high-risk HR+/HER2- early breast cancer.
Key Takeaways:
- Endocrine therapy alone led to a 5-year dDFS >96% in select low-risk patients, avoiding chemotherapy.
- Nab-paclitaxel vs. paclitaxel showed comparable survival outcomes, with nab-paclitaxel achieving higher pCR rates but more hematological toxicity.
- The ADAPTcycle trial is now investigating if CDK4/6 inhibitors can replace chemotherapy in intermediate-risk patients.
These findings highlight the ongoing evolution of precision medicine in breast cancer treatment.
